Public debate in the 1990s over drugs’ clinical toxicity has given way to concerns about their financial toxicity. Although drug regulators aren’t supposed to be concerned with pricing, they’ve been drawn into an acrimonious debate over the cost of medicines.
New report finds prevalence of 5% drug-resistant bacteria in District.
“It used to be the drug companies only took one price increase a year,” Dr. Steve Miller, chief medical officer at Express Scripts, a major drug-benefit manager, told the Times. “Now what they’re doing is taking multiple price increases multiple times a year.”
HENRY KOTULA 